Trends in antimicrobial drug development: implications for the future.

By B. Spellberg, J. Powers, E. Brass, L. Miller, J. Edwards. Clinical Infectious Diseases, 2004

864 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Molecular Medicine, Pollution

View Paper: https://www.semanticscholar.org/paper/3646f711910ed7257bda787ea834606aa975839d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

In Molecular Medicine

In Pollution

Citations in the corpus

Acinetobacter baumannii: Emergence of a Successful Pathogen (2008, background): “Compounding the problem is the large number of pharmaceutical companies that have abandoned antibiotic drug discovery and development, driven primarily by the risks of poor financial returns relative to those for more lucrative classes of drugs (519, 593).”
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, methodology): “Because no comprehensive survey of antibiotic development was undertaken before the IDSA’s reports of 2004 and 2006 [12, 14], we cannot determine whether the 388 medications and vaccines reported in development by PhRMA—or even just the new, systemic antibacterials listed in the present…”
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria (2012, background): “Unfortunately, as antimicrobial resistance is worsening, the antimicrobial armamentarium against Gram-negative bacilli remains relatively constant (236).”
Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. (2009, background): “The emergence of antimicrobial-resistant organisms is accelerating, and novel drug development is not keeping pace [1–9].”
Isolation and Characterization of Antibacterial Actinomycetes from Soil Samples of Kalapatthar, Mount Everest Region (2010, background): “Need of new antimicrobial agents is greater than ever because of emergence of multidrug resistance in common pathogens, the rapid emergence of new infections and the use of multidrug resistant pathogens in bioterrorism (Spellberg et al. 2004).”
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. (2008, neutral): “officials at the US FDA, published the first peer-reviewed data confirming the decline in the development of new antibiotics by pharmaceutical companies [42].”
Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. (2009, background): “ics have entered the market in the past 40 years (4).”
Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action. (2006, background): “That is a problem in itself, though, as the number of newly introduced antibiotics has been declining steadily, from 16 new compounds during the period of 1983 – 1987 to only 7 between 1998 and 2002 [13].”
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. (2006, methodology): “[3] were accessed, and data on drugs in development were reviewed; (4) the PubMed database was searched for relevant literature published from January 2003 through August 2005 by using the search terms “antimicrobial drug development,” “investigational antimicrobials,” and “novel antimicrobials”; an”
Improved annotation of antibiotic resistance determinants reveals microbial resistomes cluster by ecology (2014, background): “Multidrug resistance in clinical pathogens continues to rise, whereas the pipeline for new antibiotic development and approval continues to dwindle (Spellberg et al., 2004).”